Found: 12
Select item for more details and to access through your institution.
SARS-CoV-2 S protein: ACE2 interaction reveals novel allosteric targets.
- Published in:
- eLife, 2021, p. 1, doi. 10.7554/eLife.63646
- By:
- Publication type:
- Article
Defining neutralization and allostery by antibodies against COVID-19 variants.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42408-x
- By:
- Publication type:
- Article
Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. 1, doi. 10.1038/s41467-019-08790-1
- By:
- Publication type:
- Article
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
- Published in:
- PLoS ONE, 2021, v. 16, n. 6, p. 1, doi. 10.1371/journal.pone.0253487
- By:
- Publication type:
- Article
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-024-00835-x
- By:
- Publication type:
- Article
An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis.
- Published in:
- NPJ Vaccines, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41541-023-00710-1
- By:
- Publication type:
- Article
Author Correction: An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis.
- Published in:
- NPJ Vaccines, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41541-023-00710-1
- By:
- Publication type:
- Article
Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus.
- Published in:
- NPJ Vaccines, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41541-022-00516-7
- By:
- Publication type:
- Article
Switching Heavy Chain Constant Domains Denatures the Paratope 3D Architecture of Influenza Monoclonal Antibodies.
- Published in:
- Pathogens, 2023, v. 12, n. 1, p. 51, doi. 10.3390/pathogens12010051
- By:
- Publication type:
- Article
Relative deficiency in interferon‐γ‐secreting CD4+ T cells is strongly associated with poorer COVID‐19 vaccination responses in older adults.
- Published in:
- Aging Cell, 2024, v. 23, n. 4, p. 1, doi. 10.1111/acel.14099
- By:
- Publication type:
- Article
Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-49231-w
- By:
- Publication type:
- Article